This company listing is no longer active
Mithra Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Mithra Pharmaceuticals does not have a record of paying a dividend.
Key information
0%
Dividend yield
-15.1%
Buyback Yield
| Total Shareholder Yield | -15.1% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 0% |
Recent dividend and buyback updates
No updates
Recent updates
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%
Apr 06
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive
Feb 07Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts
Nov 09These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts
Oct 05Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)
May 23Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts
Aug 11Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%
Mar 13Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt
Dec 22Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 24Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt
Jun 07When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?
May 10Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?
Mar 18We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings
Feb 16Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long
Jan 21
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates
Nov 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if MITRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MITRA's dividend payments have been increasing.
Dividend Yield vs Market
| Mithra Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MITRA) | 0% |
| Market Bottom 25% (BE) | 2.5% |
| Market Top 25% (BE) | 7.6% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast (MITRA) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate MITRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MITRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: MITRA is not paying a notable dividend for the Belgian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MITRA has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/20 03:25 |
| End of Day Share Price | 2024/09/18 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mithra Pharmaceuticals SA is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Allen | Berenberg |
| Maxime Stranart | ING Groep NV |
| Thomas Landemaine | Kepler Cheuvreux |